Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Healthcare Biotechnology
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Sirona Biochem Corp
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Dachs1on Sep 17, 2016 4:02am
161 Views
Post# 25247820

RE:RE:Realistic purchase price and science comparison

RE:RE:Realistic purchase price and science comparison
hcdtrading wrote: AGN has a market cap of close to 100 Billion so writing a cheque to SBM for 300-500 million is basically an accounting error for them on one of their quarters.


With "only" positiv Cash Flow from Operations(1,382 MUSD in Q2) and (1,218 MUSD in Q1) to issuce 3-4 cheques of 500 MUSD per quarter is significant. Note that Allergan also take over the people of the such transations = fix costs without any revenues (or little revenues). 

Perhaps we (special me) focus us to much on Allergan. Of course Allergan has now a lot of money to spent but i still hope our partner for 1067 is Shiseido or L'Oreal  (second choice AmorePacific or a Chinese cosmetic company) unless e.g. Allergan or a Chinese compnay buys the whole company.







Bullboard Posts
Dealroom for high-potential pre-IPO opportunities